Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL8762418 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL30411640 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29425180 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL418079 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29846205 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL1611636 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996742-A | Methods and agents for glaucoma | 奥夫博医疗创新有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4306121-B1 | METHOD FOR OBTAINING CANNABIS EXTRACT AND USES THEREOF | OILS4CURE S L (ES) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025056075-A1 | MUSCLE RELAXANT ANTAGONIST FOR REVERSAL FOR BENZYLISOQUINOLINE MUSCLE RELAXANT | 杭州奥默医药股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| EP-4306121-A1 | METHOD FOR OBTAINING CANNABIS EXTRACT AND USES THEREOF | Oils4Cure, S.L. (ES) | 2024-01-17 | — | — | EP | disclosed |
| CN-117279632-A | TAAR1 and serotonin modulators, pharmaceutical compositions thereof, and methods of use | 赛诺维信制药公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11827653-B2 | Tridentate macrocyclic compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116456972-A | Prolonged release pharmaceutical formulations | 道格拉斯制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-110612310-B | anti-CLDN-5 antibodies and medicaments containing the same | 国立大学法人大阪大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230040709-A1 | TRIDENTATE MACROCYCLIC COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-02-09 | — | — | US | disclosed |
| CN-110035763-B | Composition for treating parasitic diseases | 瑞阳公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115135317-A | Reducing side effects of NMDA antagonists | 西洛斯治疗有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220312223-A1 | STATION PLACEMENT ASSISTANCE METHOD | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2022-09-29 | — | — | US | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114716544-A | Complement component C5 antibody | 阿勒根公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114667084-A | Non-animal soft gel capsule preparation, preparation method and using method thereof | R.P.谢勒技术有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114340733-A | Regeneration of connective tissue function and phenotype by Npas2 inhibition | 加利福尼亚大学董事会 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040709-A1 | TRIDENTATE MACROCYCLIC COMPOUNDS | CBR3, NOX3, CYB5R3 | DRD3 326/4885DRD2 969/4885DRD4 253/4885 |
| US-11827653-B2 | Tridentate macrocyclic compounds | CBR3, NOX3, CYB5R3 | DRD3 326/4885DRD2 969/4885DRD4 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.